Characteristics of patients with BA-fatigue compared to patients with other ADRs and without ADRs
| Patients with BA-fatigue n (%) | Patients with other ADRs n (%) | Patients without ADRs n (%) | ||
|---|---|---|---|---|
| n | 100 (100%) | 596 (100%) | 673 (100%) | |
| Basic demographics | Age (years) (mean ± SD) | 50.0 ± 14.6 | 53.4 ± 13.6 * | 55.7 ± 14.2 *** |
| Gender (Female) | 59 (59%) | 398 (67%) ns | 342 (51%) ns | |
| Smoking n (%) | 25 (25%) | 97 (16%) * | 100 (15%) * | |
| BMI (kg/m2) (mean ± SD) | 25.7 ± 4.4 | 25.9 ± 4.7 ns | 26.6 ± 5.5 ns | |
| Biologic | Infliximab | 22 (22%) | 53 (9%) *** | 84 (12%) * |
| Etanercept | 13 (13%) | 177 (30%) *** | 228 (34%) *** | |
| Rituximab | 9 (9%) | 18 (3%) ** | 6 (1%) *** | |
| Tocilizumab | 8 (8%) | 29 (5%) ns | 13 (2%) ** | |
| Vedolizumab | 7 (7%) | 12 (2%) * | 7 (1%) *** | |
| IMID | Rheumatoid arthritis | 29 (29%) | 270 (45%) ** | 272 (40%) * |
| Crohn’s disease | 29 (29%) | 77 (13%) *** | 88 (13%) *** | |
| Other indication | 16 (16%) | 53 (9%) * | 39 (6%) *** | |
| Combination therapy | Methotrexate | 23 (23%) | 167 (28%) ns | 227 (34%) * |
| Comorbidity | Psychiatric disorder | 11 (11%) | 49 (8%) ns | 31 (5%) * |
| Other comorbidity | 30 (30%) | 124 (21%) * | 102 (15%) *** | |
| Mean burden of ADR ± SD | 2.9 ± 0.9 | 2.4 ± 1.1 *** | ||
ns: not significant *p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001